Patients with neovascular age-related macular degeneration (wet-AMD) have some solid treatment options that can decrease the amount of visual acuity loss due to the disease. Roche's (OTCQX:RHHBY) Lucentis is the most commonly recognized of the treatments and was approved in 2006, bringing in $1.5 billion in sales for 2012. A newer therapeutic, Regeneron's (NASDAQ:REGN) Eylea, has gone on an explosive run, increasing sales in 1Q 2013 nearly 90% from 1Q2012, with sales of $837.9 million for 2012, the first year of FDA approval. However, both of these treatments, and others not mentioned, require patients to undergo an intravitreal injection. An intravitreal injection is literally an injection directly into the eye, targeting the vitreous humor,...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|